Keyphrases
AIDS/HIV
100%
High Risk
100%
Non-Hodgkin Lymphoma
100%
R-EPOCH
100%
Vorinostat
100%
Chemotherapy
30%
Combined Antiretroviral Therapy (cART)
23%
Epstein-Barr Virus-positive
23%
Viral Load
15%
Clinical High Risk
15%
CD4 Count
15%
Cyclophosphamide
15%
Event-free Survival
15%
Phase I Trial
15%
Etoposide
15%
Prednisone
15%
Dose-limiting Toxicity
15%
Rituximab
15%
HHV-8
15%
Steady-state Concentration
15%
Doxorubicin Hydrochloride
15%
Sepsis
7%
Viral
7%
Confidence Interval
7%
Diffuse Large B-cell Lymphoma (DLBCL)
7%
Tumor
7%
Safe Dose
7%
Antitumor Effect
7%
Abscess
7%
Histone Deacetylase Inhibitor (HDACi)
7%
Cell Killing
7%
Recommended Phase 2 Dose
7%
Neutropenia
7%
Thrombocytopenia
7%
Response Rate
7%
Complete Response Rate
7%
Primary Effusion Lymphoma
7%
Cytotoxic Chemotherapy
7%
B-cell non-Hodgkin Lymphoma (B-NHL)
7%
Antiretroviral Therapy Regimens
7%
3 + 3 Design
7%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Non-Hodgkin Lymphoma
100%
Vorinostat
100%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Chemotherapy
30%
Antiretroviral Therapy
23%
Epstein Barr Virus
23%
Cell Count
15%
Neoplasm
15%
Steady State
15%
Event Free Survival
15%
Phase I Trials
15%
Cyclophosphamide
15%
Etoposide
15%
Prednisone
15%
Vincristine
15%
Doxorubicin
15%
Human Herpesvirus 8
15%
Rituximab
15%
Sepsis
7%
Diffuse Large B-Cell Lymphoma
7%
B Cell
7%
Histone Deacetylase Inhibitor
7%
Neutropenia
7%
Thrombocytopenia
7%
Primary Effusion Lymphoma
7%
Cytotoxic Chemotherapy
7%
Patient with Non-Hodgkins Lymphoma
7%
Cell Killing
7%
Dental Abscess
7%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Nonhodgkin Lymphoma
100%
Vorinostat
100%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Chemotherapy
30%
Epstein-Barr Virus
23%
Neoplasm
15%
Cyclophosphamide
15%
Event Free Survival
15%
Phase I Trials
15%
Doxorubicin
15%
Etoposide
15%
Prednisone
15%
Vincristine
15%
Rituximab
15%
Human Herpesvirus 8
15%
Sepsis
7%
Diffuse Large B Cell Lymphoma
7%
Histone Deacetylase Inhibitor
7%
Thrombocytopenia
7%
Neutropenia
7%
Cytotoxic Chemotherapy
7%
Tooth Abscess
7%
Primary Effusion Lymphoma
7%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Epstein Barr Virus
42%
Viral Load
28%
B Cell
28%
CD4 Lymphocyte Count
28%
Prednisone
28%
Rituximab
28%
Cyclophosphamide
28%
Human Herpesvirus 8
28%
Event Free Survival
28%
Concentration at Steady-State
28%
Cell Killing
14%
Teeth
14%
Abscess
14%